中国循证心血管医学杂志2024,Vol.16Issue(7) :769-771,797.DOI:10.3969/j.issn.1674-4055.2024.07.01

《中成药治疗优势病种临床应用指南》引文与证据类型分析

"Clinical application guidelines of Chinese patent medicines for treatment of dominant diseases":an anal-ysis on citations and evidence types

王建新 孙瑞 高学敏 孙媛媛 高蕊
中国循证心血管医学杂志2024,Vol.16Issue(7) :769-771,797.DOI:10.3969/j.issn.1674-4055.2024.07.01

《中成药治疗优势病种临床应用指南》引文与证据类型分析

"Clinical application guidelines of Chinese patent medicines for treatment of dominant diseases":an anal-ysis on citations and evidence types

王建新 1孙瑞 2高学敏 3孙媛媛 4高蕊5
扫码查看

作者信息

  • 1. 100091 北京,中国中医科学院西苑医院;100700 北京,中国中医科学院博士后流动站;100091 北京,国家药品监督管理局中药临床研究与评价重点实验室
  • 2. 100105 北京,北京中医药大学;101121 北京,北京中医药大学东直门医院
  • 3. 100105 北京,北京中医药大学
  • 4. 100061 北京,《中成药治疗优势病种临床应用指南》标准化项目组
  • 5. 100091 北京,中国中医科学院西苑医院;100091 北京,国家药品监督管理局中药临床研究与评价重点实验室
  • 折叠

摘要

目的 分析《中成药治疗优势病种临床应用指南》引文和推荐意见的证据类型及特征,为后续中医药临床指南的制定充分合理利用研究证据而提供指导意见.方法 纳入《中成药治疗优势病种临床应用指南》标准化项目和公开发表的指南,提取指南推荐意见的引文信息并进行分析.结果 共纳入29篇《中成药治疗优势病种临床应用指南》,包含262条推荐意见和2308条引文.平均每篇指南引用89篇证据,平均每条推荐意见引用8篇证据.证据文献类型主要为随机对照研究,占比89%,系统评价仅占比0.9%.结论《中成药治疗优势病种临床应用指南》系列指南推荐意见明确,引文量显著增加,但仍存引用证据不全面、证据质量较差等问题.中医药指南制订者应合理利用当前可得的多种证据,拓宽证据来源,重视系统评价在推荐意见形成中的地位和意义.

Abstract

Objective To analysis the evidence types and characteristics of citations and recommend ations in"clinical application guidelines of Chinese patent medicines for treatment of dominant diseases",and provide instruction for fully and reasonably utilizing evidence in making clinical guidelines of traditional Chinese medicine(TCM)in the future.Methods The standardized items and published guidelines were cooptated into a series of"clinical application guidelines of Chinese patent medicines for treatment of dominant diseases",and information of citations and recommend ations were extracted and analyzed.Results There were totally 29"clinical application guidelines of Chinese patent medicines for treatment of dominant diseases"included with 262 recommend ations and 2308 citations.An average of 89 evidences were cited in each guideline and 8 evidences were cited in each recommend ation.The main type of evidence literature was randomized controlled trails,which accounting for 89%,and systematic reviews only accounted for 0.9%.Conclusion A series of"clinical application guidelines of Chinese patent medicines for treatment of dominant diseases"have definite recommend ations and increased citations,but there are problems of incomplete cited evidences and low-quality evidences.The developers of TCM guidelines should rationally utilize various available evidences at present,broaden evidence sources,and pay attention to position and the signification of systematic review in recommend ation formation.

关键词

中成药/指南/引文/证据类型

Key words

Chinese Patent Medicines/Guideline/citations/Evidence types

引用本文复制引用

出版年

2024
中国循证心血管医学杂志
中国人民解放军北京军区总医院

中国循证心血管医学杂志

CSTPCD
影响因子:1.272
ISSN:1674-4055
段落导航相关论文